NRXS Neuraxis, INC
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1933567 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY94.3%
TTM net income YoY-60.5%
TTM EPS YoY-9.1%
Revenue 3-yr CAGR37.0%
Net income 3-yr CAGR—
Margins
Gross margin86.2%
Operating margin-186.2%
Net margin-185.2%
FCF margin—
EBITDA margin-185.0%
Returns
ROE-409.7%
ROA-194.7%
ROIC (approx.)—
Asset turnover1.05x
Leverage & solvency
Liabilities / assets45.6%
Debt / equity0.00x
Current ratio2.10x
Interest coverage-128.36x
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio-90.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $3.57M | $2.69M | $2.46M | $2.68M |
| Cost of revenue | $562,916 | $362,002 | $303,345 | $297,060 |
| Gross profit | $3.01M | $2.32M | $2.16M | $2.39M |
| R&D expense | $493,611 | $433,614 | $169,315 | $225,610 |
| SG&A expense | $8.06M | $7.58M | $8.33M | $5.12M |
| Operating income | -$7.83M | -$7.16M | -$6.66M | -$3.37M |
| Interest expense | $73,969 | $174,328 | $476,416 | $318,666 |
| Net income | -$7.80M | -$8.24M | -$14.63M | -$4.78M |
| EBITDA | -$7.77M | -$7.12M | -$6.62M | -$3.34M |
| EPS (basic) | -0.95 | -1.22 | -4.50 | -2.77 |
| EPS (diluted) | -0.95 | -1.22 | -4.50 | -2.77 |
| Weighted avg. shares (diluted) | 9.08M | 6.92M | 3.25M | 2.00M |
| Banking | ||||
| Deposits | $28,660 | $32,527 | $74,947 | $59,174 |
| Balance sheet | ||||
| Cash & equivalents | $4.97M | $3.70M | $78,560 | $253,699 |
| Receivables | $195,703 | $244,618 | $73,167 | $174,399 |
| Inventory | $257,132 | $44,328 | $21,220 | $48,133 |
| Current assets | $5.73M | $4.27M | $242,610 | $476,957 |
| PP&E, net | $75,564 | $89,982 | $88,552 | $88,011 |
| Intangibles | $274,778 | $96,588 | $108,073 | $77,558 |
| Total assets | $6.40M | $4.76M | $509,498 | $1.48M |
| Current liabilities | $2.79M | $2.43M | $1.89M | $6.98M |
| Short-term debt | $148,293 | $154,152 | $148,062 | — |
| Long-term debt | — | — | — | $228,342 |
| Total debt | — | — | — | $228,342 |
| Total liabilities | $3.00M | $2.69M | $1.91M | $7.05M |
| Shareholders' equity | $3.40M | $2.07M | -$1.40M | -$5.57M |
| Net debt | — | — | — | -$25,357 |
| Shares outstanding | 10.65M | 6.99M | 6.51M | 1.96M |
| Cash flow statement | ||||
| Operating cash flow | -$6.43M | -$6.10M | -$6.69M | -$2.30M |
| Capital expenditure | $31,150 | $27,776 | $30,781 | $1,390 |
| Free cash flow | -$6.46M | -$6.13M | -$6.72M | -$2.30M |
| Investing cash flow | -$131,150 | -$27,776 | -$71,781 | -$61,205 |
| Financing cash flow | $7.83M | $9.74M | $6.59M | $2.29M |
| Depreciation & amortization | $59,501 | $37,831 | $40,725 | $37,133 |
| Stock-based compensation | $596,852 | $227,000 | — | $27,319 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.